Systems Biology Goes Commercial As Integrated Diagnostics Launches Lung Nodule Test
This article was originally published in Start Up
With the launch of its Xpresys Lung test, Integrated Diagnostics joins the ranks of commercial molecular diagnostics companies offering tests to help physicians characterize suspicious tissue. But unlike other tests on the market and in development, the Xpresys Lung test is designed to be used early in the process – before a biopsy is even ordered.
You may also be interested in...
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
Concerns over patents, the anticipated regulatory oversight over complex tests, and reimbursement and evidence development characterized the continued upheaval in the diagnostics industry over the past year. However, genomics tools and technologies continue to be refined and introduced commercially, and companies with a sharp marketplace focus are showing they can still rise to the top.
Veracyte has launched a complex molecular diagnostic test in thyroid in record time and with impressive capital efficiency. It could be a model for high-value diagnostics, especially if the company can successfully adopt its approach in a broader market.